For more information on Age-Related Macular Degeneration go to the NHS website. If you've had a diagnosis, in addition to ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

Macular degeneration is one of the leading causes of vision loss, affecting millions worldwide, especially those over 60.

The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

The unique challenges, and need for awareness, of age-related macular degeneration (AMD) is now formally recognized in Canada ...

Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company advancing a new class of nanomedicine therapeutics that traverse tissue barriers to selectively target and reprogram activated cells in ...

Collaboration between TLI and AMDF underscores a shared commitment to making a meaningful difference in the lives of those ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

This research team evaluated the effectiveness of switching patients to faricimab treatment by assessing their outcomes after ...

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to treat vision-threatening eye diseases, including wet age-related macular degeneration (wet AMD) and diabetic ...

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a ...

INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the ...